Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.80.

A number of equities analysts have recently weighed in on ALT shares. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Piper Sandler reissued an “overweight” rating and issued a $25.00 price objective on shares of Altimmune in a research report on Friday, June 21st. Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Finally, B. Riley reissued a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Monday, August 12th.

Insider Buying and Selling at Altimmune

In other news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the transaction, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Altimmune

A number of institutional investors have recently modified their holdings of ALT. Farallon Capital Management LLC lifted its stake in Altimmune by 1,282.4% in the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after purchasing an additional 436,000 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Altimmune in the fourth quarter worth about $4,493,000. Knoll Capital Management LLC increased its holdings in Altimmune by 183.6% during the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after purchasing an additional 367,219 shares during the period. Dimensional Fund Advisors LP raised its position in Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. Finally, Gerber LLC purchased a new stake in Altimmune in the 4th quarter worth approximately $2,878,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Stock Performance

Shares of ALT opened at $6.47 on Friday. The firm has a market capitalization of $458.74 million, a P/E ratio of -4.07 and a beta of 0.08. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84. The stock has a 50 day moving average price of $6.68 and a two-hundred day moving average price of $7.28.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The company had revenue of $0.01 million for the quarter. During the same period in the prior year, the business earned ($0.32) EPS. On average, equities analysts forecast that Altimmune will post -0.54 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.